Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the
“Company”) today announced that it will release its second quarter
2021 financial results on Thursday, August 5, 2021, after the
markets close. Aurinia’s management team will also host a
conference call at 4:30 p.m. EDT to discuss the Company’s financial
results and to provide a general business update.
The conference call and webcast is scheduled for August 5, 2021
at 4:30 p.m. ET. In order to participate in the conference call,
please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio
webcast can be accessed under "News/Events” through the “Investors”
section of the Aurinia corporate website at www.auriniapharma.com.
A replay of the webcast will be available on Aurinia’s website.
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. The Company has introduced LUPKYNIS™ (voclosporin),
the first FDA-approved oral therapy dedicated for the treatment of
adult patients with active lupus nephritis (LN). The Company’s head
office is in Victoria, British Columbia, its U.S. commercial hub is
in Rockville, Maryland, and the Company focuses its development
version on businesswire.com: https://www.businesswire.com/news/home/20210726005060/en/
Investor Contact: Glenn Schulman, PharmD, MPH SVP,
Corporate Communications & IR firstname.lastname@example.org